155 related articles for article (PubMed ID: 30170409)
21. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma.
Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA
Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507
[TBL] [Abstract][Full Text] [Related]
22. MDM2 binding protein, a novel metastasis suppressor.
Iwakuma T; Agarwal N
Cancer Metastasis Rev; 2012 Dec; 31(3-4):633-40. PubMed ID: 22684342
[TBL] [Abstract][Full Text] [Related]
23. Prognostic impact of GATA binding protein-3 expression in primary lung adenocarcinoma.
Hashiguchi T; Miyoshi H; Nakashima K; Yokoyama S; Matsumoto R; Murakami D; Mitsuoka M; Takamori S; Akagi Y; Ohshima K
Hum Pathol; 2017 May; 63():157-164. PubMed ID: 28322854
[TBL] [Abstract][Full Text] [Related]
24. [Expression of transcription factor SOX12 in lung adenocarcinoma and its clinical significance].
Li L; Zhang T; Chen Y; Song J; Meng Y; Liu S; Xie J
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Feb; 39(2):186-191. PubMed ID: 30890507
[TBL] [Abstract][Full Text] [Related]
25. Down-regulation of SIX3 is associated with clinical outcome in lung adenocarcinoma.
Mo ML; Okamoto J; Chen Z; Hirata T; Mikami I; Bosco-Clément G; Li H; Zhou HM; Jablons DM; He B
PLoS One; 2013; 8(8):e71816. PubMed ID: 23977152
[TBL] [Abstract][Full Text] [Related]
26. Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma.
Kachala SS; Bograd AJ; Villena-Vargas J; Suzuki K; Servais EL; Kadota K; Chou J; Sima CS; Vertes E; Rusch VW; Travis WD; Sadelain M; Adusumilli PS
Clin Cancer Res; 2014 Feb; 20(4):1020-8. PubMed ID: 24334761
[TBL] [Abstract][Full Text] [Related]
27. Expression of Tiam1 predicts lymph node metastasis and poor survival of lung adenocarcinoma patients.
Liu S; Li Y; Qi W; Zhao Y; Huang A; Sheng W; Lei B; Lin P; Zhu H; Li W; Shen H
Diagn Pathol; 2014 Mar; 9():69. PubMed ID: 24661909
[TBL] [Abstract][Full Text] [Related]
28. Chaperone protein L-isoaspartate (D-aspartyl) O-methyltransferase as a novel predictor of poor prognosis in lung adenocarcinoma.
Saito H; Yamashita M; Ogasawara M; Yamada N; Niisato M; Tomoyasu M; Deguchi H; Tanita T; Ishida K; Sugai T; Yamauchi K
Hum Pathol; 2016 Apr; 50():1-10. PubMed ID: 26997432
[TBL] [Abstract][Full Text] [Related]
29. Beclin 1 and p62 expression in non-small cell lung cancer: relation with malignant behaviors and clinical outcome.
Wang X; Du Z; Li L; Shi M; Yu Y
Int J Clin Exp Pathol; 2015; 8(9):10644-52. PubMed ID: 26617774
[TBL] [Abstract][Full Text] [Related]
30. MDM2 gene amplification: a new independent factor of adverse prognosis in non-small cell lung cancer (NSCLC).
Dworakowska D; Jassem E; Jassem J; Peters B; Dziadziuszko R; Zylicz M; Jakóbkiewicz-Banecka J; Kobierska-Gulida G; Szymanowska A; Skokowski J; Roessner A; Schneider-Stock R
Lung Cancer; 2004 Mar; 43(3):285-95. PubMed ID: 15165086
[TBL] [Abstract][Full Text] [Related]
31. High PHLPP expression is associated with better prognosis in patients with resected lung adenocarcinoma.
Lv D; Yang H; Wang W; Xie Y; Hu W; Ye M; Chen X
BMC Cancer; 2015 Oct; 15():687. PubMed ID: 26463718
[TBL] [Abstract][Full Text] [Related]
32. Identification of common prognostic gene expression signatures with biological meanings from microarray gene expression datasets.
Yao J; Zhao Q; Yuan Y; Zhang L; Liu X; Yung WK; Weinstein JN
PLoS One; 2012; 7(9):e45894. PubMed ID: 23029298
[TBL] [Abstract][Full Text] [Related]
33. Regulation of p53 and MDM2 activity by MTBP.
Brady M; Vlatkovic N; Boyd MT
Mol Cell Biol; 2005 Jan; 25(2):545-53. PubMed ID: 15632057
[TBL] [Abstract][Full Text] [Related]
34. A Seven-Gene Signature with Close Immune Correlation Was Identified for Survival Prediction of Lung Adenocarcinoma.
Zou X; Hu Z; Huang C; Chang J
Med Sci Monit; 2020 Jul; 26():e924269. PubMed ID: 32613949
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of junctional adhesion molecule-A and EphB2 predicts poor survival in lung adenocarcinoma patients.
Zhao C; Wang A; Lu F; Chen H; Fu P; Zhao X; Chen H
Tumour Biol; 2017 Feb; 39(2):1010428317691000. PubMed ID: 28231727
[TBL] [Abstract][Full Text] [Related]
36. Elevated MACC1 expression predicts poor prognosis in small invasive lung adenocarcinoma.
Guo T; Zhao S; Li Z; Li F; Li J; Gu C
Cancer Biomark; 2018; 22(2):301-310. PubMed ID: 29630522
[TBL] [Abstract][Full Text] [Related]
37. The Long Intergenic Noncoding RNA 00707 Promotes Lung Adenocarcinoma Cell Proliferation and Migration by Regulating Cdc42.
Ma T; Ma H; Zou Z; He X; Liu Y; Shuai Y; Xie M; Zhang Z
Cell Physiol Biochem; 2018; 45(4):1566-1580. PubMed ID: 29482190
[TBL] [Abstract][Full Text] [Related]
38. Non-terminal respiratory unit type lung adenocarcinoma has three distinct subtypes and is associated with poor prognosis.
Sumiyoshi S; Yoshizawa A; Sonobe M; Kobayashi M; Sato M; Fujimoto M; Tsuruyama T; Date H; Haga H
Lung Cancer; 2014 Jun; 84(3):281-8. PubMed ID: 24725383
[TBL] [Abstract][Full Text] [Related]
39. Prognostic potential of the MDM2 309T>G polymorphism in stage I lung adenocarcinoma.
Enokida Y; Shimizu K; Atsumi J; Kakegawa S; Takase Y; Kaira K; Yashima H; Araki T; Nakazawa S; Ohtaki Y; Nagashima T; Alexander L; Usui K; Ishikawa T; Hayashizaki Y; Takeyoshi I
Cancer Med; 2016 Aug; 5(8):1791-801. PubMed ID: 27228500
[TBL] [Abstract][Full Text] [Related]
40. Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA).
Sperduto PW; Yang TJ; Beal K; Pan H; Brown PD; Bangdiwala A; Shanley R; Yeh N; Gaspar LE; Braunstein S; Sneed P; Boyle J; Kirkpatrick JP; Mak KS; Shih HA; Engelman A; Roberge D; Arvold ND; Alexander B; Awad MM; Contessa J; Chiang V; Hardie J; Ma D; Lou E; Sperduto W; Mehta MP
JAMA Oncol; 2017 Jun; 3(6):827-831. PubMed ID: 27892978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
